Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Sarangdev Vaidya

Ophthalmology Eatontown, NJ Medical Doctor

NPI 1740865120 CMS profile 11887634

300 Highway 35, Eatontown, NJ 07724

Open in the dashboard

General payments

$119

6 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarangdev Vaidya of Eatontown, NJ is reported in the CMS Open Payments database as having received $119 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 12th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $119 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarangdev Vaidya
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Sarangdev Vaidya were reported at $119. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Sarangdev Vaidya Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $119 $384 $136–$917 $169

Breakdown

Who paid General payments · program year 2025
  1. Tarsus Pharmaceuticals, Inc. $59 3 payments
  2. Harrow Eye, LLC $24 1 payment
  3. Sun Pharmaceutical Industries Inc. $20 1 payment
  4. ANI Pharmaceuticals, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $119 6 payments
Products named General payments · program year 2025
  1. XDEMVY $59 3 payments
  2. VEVYE $24 1 payment
  3. Cequa $20 1 payment
  4. PURIFIED CORTROPHIN GEL $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

368

Median for Ophthalmology: 891

Drug cost

$10,785

Median for Ophthalmology: $68,233

Branded share of claims

21.7%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rhopressa Netarsudil Mesylate Brand 11 $3,300
Prednisolone Acetate Generic 72 $2,862
Brimonidine Tartrate Generic 94 $1,902
Latanoprost Generic 98 $1,301
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 69 $1,062
Dorzolamide Hcl Generic 24 $358

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record